The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 victory for Roche’s Enspryng suggests a first-of-its-kind FDA approval may not ...
"Patients with anti-AQP4-Ab may basically need long-term relapse prevention, because they surely experience much higher relapse activity, with much worse neurological disturbance…In MOGAD patients, ...
Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a condition of the nervous system that can be managed with lifestyle modifications or medications, depending on your individual needs.
The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Treatment with satralizumab reduced the risk of new MOGAD relapse by 68% vs placebo. Positive results were announced from a phase 3 trial evaluating satralizumab for the treatment of myelin ...
CHICAGO — Satralizumab (Enspryng), a humanized monoclonal antibody, was associated with a significant reduction in relapse risk compared with placebo in myelin oligodendrocyte glycoprotein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results